On January 10, Samsung Bioepis announced a new arrangement with Teva to commercialize the former’s eculizumab biosimilar Epysqli (reference product, Soliris) in the US. In a press release, Kyung-Ah Kim, the recently promoted President and CEO of Samsung Bioepis, stated “We are excited to announce this new strategic partnership for a biosimilar which has a … Continue reading Samsung Bioepis and Teva Ink a Deal for Epysqli; Tanvex Gets a Thumbs Down